Thirteen hepatitis B surface antigen-positive Chinese patients who received hepatitis B surface antibody-positive marrow (hepatitis B core antibody-positive or -negative: 6 and 7, respectively) via allogeneic bone marrow transplantation (BMT) were studied. After BMT, 4 recipients had serologic clearance of hepatitis B surface antigen from hepatitis B core antibody-positive marrow, but none of the recipients of hepatitis B core antibody-negative marrow had serologic clearance ( ). There was no significant difference in the donors' P ϭ .02 hepatitis B surface antibody titer before BMT for patients with or without serologic clearance of hepatitis B surface antigen ( vs. mIU/mL; signifi-2255.2 ‫ע‬ 4244.0 854.2 ‫ע‬ 2306.7 P ϭ not cant). Adoptive immunity clearance of hepatitis B surface antigen was favored by hepatitis B core antibody positive-donor marrow and was not related to donor pre-BMT hepatitis B surface antibody titer.
with engraftment of hepatitis B surface antibody (anti-HBs)-positive marrow. However, only 2 of 5 HBsAg-positive recipients who received anti-HBs-positive marrow had serologic clearance of HBsAg [7] . This suggested that other factors might be important in determining the HBV viral response to adoptive immunity transfer. It is controversial whether vaccinating the donor with conventional hepatitis B vaccine alone would be adequate for effective serologic clearance of HBsAg [8, 9] . Moreover, the safety issue of this immunologic approach had been questioned [10] . Our aims were to study the clinical and virologic outcomes of HBsAg-positive recipients of antiHBs-positive marrow (natural immunity/vaccination) and to determine whether donor hepatitis B core antibody (anti-HBc) status and anti-HBs titer would affect serologic clearance of HBsAg.
Patients and Methods
Between April 1995 and May 1998, 126 patients received allogeneic BMT at Queen Mary Hospital, Hong Kong. All recipients and donors of allogeneic BMT were screened for HBsAg, antiHBs, hepatitis C antibodies (anti-HCV), and human immunodeficiency virus antibodies (anti-HIV). HBsAg-positive subjects were further tested for hepatitis B e antigen (HBeAg), hepatitis B e antibody (anti-HBe), and antibody to hepatitis D virus (anti-HDV). Thirteen HBsAg-positive Chinese recipients received HLAidentical marrow from donors who were anti-HBs-positive. The median age of the recipients was 32 years (range, . There were 8 men and 5 women. Seven were HBeAg-positive; 6 were anti-HBe-positive. Three were HBV DNA-positive by branchedchain DNA (bDNA) assay (Quantiplex HBV DNA assay; Chiron, Emeryville, CA). The underlying hematologic diseases of the BMT recipients are shown in table 1. None were coinfected with HCV (anti-HCV-negative and HCV RNA-negative). All patients were also enrolled in a prophylactic study of oral famciclovir (SmithKline Beecham, Welwyn Garden City, UK) at dosages of 250 mg three times a day or 500 mg three times a day. Liver biopsies were obtained 1-2 weeks before the initiation of famciclovir therapy for prevention of HBV reactivation. In accordance with the protocol, famciclovir was administered to HBsAg-positive recipients ≥1 week (range, 1-12) before BMT and for 24 weeks after BMT [11] . Seven patients received anti-HBs-positive marrow, and 6 received marrow that was anti-HBs-and anti-HBc-positive.
Donor anti-HBc status and anti-HBs titer (mIU/mL) were measured on the day of marrow harvest. Seven donors had a history of HBV vaccination (all were anti-HBs-positive); 6 did not (all were anti-HBs-and anti-HBc-positive). Four donors also received booster vaccination in the deltoid muscle with 10 mg of B-HE-PAVAC II (Merck Sharp & Dohme, West Point, PA) before BMT (median, 2 weeks; range, 1-3). There were no significant differences in antibody titer between the anti-HBc-positive and -negative groups on the day of marrow harvest ( vs. 2255.2 ‫ע‬ 4244.0 mIU/mL, significant [NS]). After BMT, 854.2 ‫ע‬ 2306.7 P ϭ not serial clinical, biochemical, and virologic data were recorded at weekly intervals for 3 months and then at 2-to 4-week intervals for 1 year. Hepatitis B serology was tested by EIA and serum HBV DNA by bDNA and polymerase chain reaction (PCR) assays as described below.
Definitions of hepatic events. Serologic clearance of HBsAg was defined as loss of serologic HBsAg accompanied by the presence of anti-HBs and the absence of serum HBV DNA as detected by bDNA assay. Serologic clearance of HBsAg was defined as transient if it lasted !6 months after HBsAg seroconversion and sustained if it lasted 16 months. Hepatitis was defined as a 13-fold elevation of serum alanine aminotransferase on two consecutive determinations ≥5 days apart in the absence of clinical features suggestive of venoocclusive disease, hepatic graft-versus-host disease (GVHD), or superinfection of cytomegalovirus and herpes simplex virus. Venoocclusive disease was defined as development of two or more of the following features within 30 days after BMT: jaundice, hepatomegaly and right upper quadrant pain, ascites, or unexplained weight gain [12] . Hepatic GVHD was defined as the presence of clinical or histologic evidence of other target organ (skin and gut) involvement with GVHD in conjunction with the development of abnormal serum liver biochemistry [13] . Hepatic failure was defined as the presence of hepatic encephalopathy and deranged blood coagulation (prothrombin time 110 s above normal).
Hepatitis serology and HBV DNA assay and HCV reverse transcription (RT)-PCR assay. Hepatitis B serologic markers, including HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HCV (EIA II), anti-hepatitis D virus, and anti-HIV, were tested by commercial EIA (Abbott Laboratories, Abbott Park, IL). Total anti-HBc was tested by RIA (Corab; Abbott). Anti-HBs titers were determined by ELISA (Abbott) according to the manufacturer's recommendations. Anti-HBs levels were converted to milliinternational units per milliliter by use of a standard serum.
Hepatitis B DNA quantitation was done by bDNA assay as described [14] . For the surface region, the primers were CCT-GCTGGTGGCTCCAGTTC (map position 58-77) and CAAAC-GGGCAACATACCTTG (476-457) for the first round of PCR and ACATCAGGATTCCTAGGACC (169-188) and CGCAGA-CACATCCAGCGATA (398-370) for the second round. The corresponding primer sets for the core region were GGAGTGT-GGATTCGCATCCTCC (2269-2288) and ATACTAACATTGA-GATTCCC (2457-2438) and AGACCACCAAATGCCCCTAT (2299-2318) and GATCTTCTGCGACGCGGCGA (2429-2410). Serial samples from the same patient were tested within a single run to minimize interassay variation. A nested PCR assay for the detection of serum HBV DNA used primer sets from the surface antigen and the core antigen coding region [7] . Using serial dilution of EuroHep-2 HBV DNA plasma standards, the detection limits of the bDNA assay and PCR were estimated to be and 5 7 ϫ 10 genomes/mL, respectively. were designed from the highly conserved 5 noncoding region [15] .
The precore HBV sequence was determined by direct sequencing of HBV DNA amplified by PCR using primers that flanked the precore region, P1 (5 -TCCTCTGCCGATCCATACTG, position 1254-1273) and BC1 (5 -GGAAAGAAGTCAGAAGGCAA, position 1974-1955) at 50 pmol. The PCR products were directly sequenced with the "fmol" sequencing kit (Promega, Southampton, UK). Sequencing primer BC1 was end-labeled with 25 mCi of 32 Padenosine triphosphase (Amersham International, Amersham, UK) in a 10 mL volume using 10 U of polynucleotide kinase (Boehringer Mannheim, Penzberg, Germany) for 20 min at 37ЊC. We used 1.5 mL of the reaction mix in sequencing reactions. In total, 90 mL of PCR product was precipitated with an equal volume of 4 mol/L sodium acetate and 2 vol of isopropanol for 10 min at room temperature, pelleted by centrifugation for 10 min, and then washed twice with 70% ethanol. After resuspension in 20 mL of water, 9.5 mL of DNA was added to the reaction buffer with the end-labeled primer and 5 U of Taq enzyme. Dideoxynucleotide termination sequencing was performed according to the manufacturer's instructions. Cycle sequencing was done for 30 rounds. Denaturation, annealing, and extension steps were 30 s, 30 s, and 1 min, respectively.
Histopathology and immunohistochemical studies. Pretreatment (before initiation of famciclovir) liver biopsies were assessed blind to the source (by S.T.Y.). Both the histology and the modified histologic activity index were assessed [16] . Hepatic expression of HBsAg and HBcAg was determined by immunohistochemistry using a monoclonal antibody against HBsAg (Biogenex, San Ramon, CA) and polyclonal antibody against HBcAg (Dako, Carpenteria, CA). The expression of HBV antigens was graded according to the following scale:
, 1 ϭ !5%, -29%, -59%, and 0 ϭ nil 2 ϭ 5% 3 ϭ 30% 4 ϭ 160% [17] .
Statistical methods. We used the x 2 test or Fisher's exact analysis to compare the serologic clearance of HBsAg among recipients of donors who were anti-HBc-positive and -negative. We used Student's t test (statistical package; SPSS, Chicago) to assess pre-BMT donor anti-HBs titer for BMT recipients who did or did not have serologic clearance of HBsAg.
Results

Serologic outcome.
Four ( ). Four of 10 recipients with positive hepatocyte sur-P ϭ NS face antigen staining and none of 3 with negative staining had serologic clearance of HBsAg ( ). Of 10 recipients with P ϭ .50 positive hepatocyte nuclear core antigen staining, 4 had serologic clearance, and none of the recipients with negative hepatocyte nuclear core antigen staining had serologic clearance of HBsAg ( ). At their last follow-up, 1 of 2 patients P ϭ .50 who had sustained serologic clearance of HBsAg had detectable serum HBV DNA by PCR. He remained asymptomatic and had normal liver function (table 3) .
Clinical outcome. The median follow-up period was 216 days (range, 67-967). Eight subjects developed hepatitis (3 anicteric, 3 icteric and, 2 hepatic failure). Of the 3 patients who received anti-HBc-negative marrow, 2 progressed to hepatic failure, but none of 5 given anti-HBc-positive marrow developed hepatic failure (  ; table 2 ). Hepatitis was related P ϭ .11 to serologic clearance of HBsAg in 4 (2 transient, 2 sustained), to HBV reactivation in 2, and to relapse and fungal infection in 1 each. There was 1 death (16.7%; due to GVHD) in recipients of anti-HBc positive-marrow and 4 deaths (57.1%; 2 due to GVHD, 1 due to fungal infection, and 1 due to relapse) among those who received anti-HBc-negative marrow (P ϭ ). .27 Discussion Four (30.8%) HBsAg-positive patients had serologic clearance of HBsAg after allogeneic BMT with anti-HBs-positive marrow. Serologic clearance of HBsAg was always preceded by hepatic flares. The exact mechanism of these flare clearances is uncertain. The timing of the flares coincided with immune reconstitution and could represent immune attack by the transplanted donor lymphocytes on HBV-bearing hepatocytes via adoptive immunity transfer [7, 18] . Previously, famciclovir was effective in reducing the intrahepatic replication of duck hepatitis B in vivo [19] . Famciclovir was the first nucleoside analogue shown to significantly reduce the level of viral covalently closed circular DNA species of duck hepatitis B virus, the key intermediate typically resistant to nucleoside analogue therapy [20] . In humans, famciclovir at a dosage of 500 mg three times a day for 16 weeks had a dose-dependent suppressive effect on HBV DNA replication [21] . However, none of the patients treated with famciclovir lost HBsAg. This, together with the short duration of treatment preceding the hepatic flares, makes it unlikely that the use of nucleoside analogues induced serologic clearance of HBsAg in our subjects.
In our prospective study, 1 of 2 persons who had sustained serologic clearance of HBsAg had detectable serum HBV DNA by nested PCR but not by bDNA assay in follow-up serum samples. The pathogenetic role of this very low level of serum HBV DNA is unknown. In persons who recover from acute hepatitis, traces of HBV DNA are often detectable in the blood for many years after clinical recovery [22, 23] . This trace of HBV DNA may maintain the cytotoxic T cell response against HBV and keep the virus under control [24] .
Not all patients who received anti-HBs-positive marrow had serologic clearance of HBsAg. This suggested that other factors, apart from anti-HBs-positive donor marrow, are important in serologic clearance of HBsAg. In our present study, 4 of 6 subjects who received anti-HBs-and anti-HBc-positive marrow had serologic clearance of HBsAg. In contrast, none of 7 subjects who received anti-HBs-positive, anti-HBc-negative marrow had serologic clearance of HBsAg. The reason for this discrepancy is unknown. The presence of anti-HBc in antiHBs-positive donors nearly always indicates past HBV infection [25] . None of the donors positive for both anti-HBs and anti-HBc had been vaccinated against HBV. The absence of serologic clearance of HBsAg in those who received antiHBs-positive marrow alone is unlikely to be due to lack of cellular immune response. Primary or booster vaccination with HBsAg peptide vaccine induces both humoral and cellular immune responses. The bone marrow of donors who have been vaccinated or given booster vaccination should contain mature antigen-activated cytotoxic T lymphocytes (CTL) that can attack and eliminate HBV-infected hepatocytes [26] . In prior studies, resolution of HBV infection required vigorous polyclonal and specific CTL responses against multiple epitopes in the HBV nucleocapsid and envelope and polymerase antigens [27] [28] [29] [30] . Therefore, the presence of immunity against HBsAg raised by vaccination may not be adequate to induce serologic clearance of HBsAg. However, immunity against HBV after recovery from natural infection would be polyclonal and multispecific against HBV and might be more capable of clearing HBV infection. In our present study, 66.7% of the chronic HBVinfected recipients of marrow with natural immunity against HBV recovered from HBV infection. Thus, there is need to consider how the vaccination strategy for donors could be improved to increase the clearance rate of chronic HBV in recipients. Would incorporation of more HBV epitopes in the vaccine be helpful?
Nucleocapsid antigens contain the most efficiently recognized epitopes for HLA class II-restricted CD4 ϩ T cell responses [2, 31, 32] . A lipopeptide-based vaccine in which an HLA-A2-restricted core protein CTL epitope from HBV is combined with a T helper epitope derived from tetanus toxoid has induced CTL responses in a dose-dependent fashion in naive volunteers but has had a lesser effect in chronically infected persons [33] . However, in a French study, 3 of 14 chronic hepatitis B patients who received three standard doses of conventional hepatitis B vaccine containing pre-S2 cleared HBV DNA [34] . Both pre-S1 and pre-S2 contain CTL and Th epitopes [35] [36] [37] , and both domains have important immunogenetic roles in augmenting hepatitis B surface antibody responses in mice and humans [37] [38] [39] [40] . They also prevent the attachment of HBV hepatocytes and are effective in clearing viruses [41, 42] . Currently, complex vaccines containing all three antigens, S, pre-S1, and pre-S2, are under investigation in our center.
One major concern about use of aggressive immunotherapy, such as adoptive immunity transfer, is the danger of precipitating massive hepatic damage during immunologic clearance of HBV. It was widely assumed that clearance during HBV infection was due to the destruction of infected hepatocytes by HBV-specific CTL. This issue was recently addressed by Caselitz et al. [43] . They demonstrated the possibility of death due to hepatic failure, at least partly related to HBV reactivation, in an HBsAg-positive recipient who received anti-HBs-and anti-HBc-positive marrow. In the woodchuck model, therapeutic vaccination can lead to fulminant hepatic failure and death [44) . In our present study, in the 4 subjects with serologic clearance of HBsAg, in all 4 the clearance was preceded by hepatic flare. These flares vary in severity. However, none of the patients subsequently died. This finding is in accordance with the transgenic mouse model and suggests that viral clearance is mainly conducted by the noncytopathic mechanism. Subsequent work showed that noncytopathic clearance was mediated via the effect of inflammatory cytokines, especially interferon-g and tumor necrosis factor-a, which are released by CTL when they recognize the HBV viral antigen on hepatocytes [45] . However, further work is needed to clarify this issue in humans. Alternatively, the low virus load of the recipients in our study (all received famciclovir) might have reduced the immune-mediated damage.
In our study, among those who received anti-HBs-and anti-HBc-positive marrow, those who had sustained clearance of HBsAg after allogeneic BMT were HBeAg-negative while only 1 of 2 recipients who did not have sustained HBsAg clearance were HBeAg-negative before BMT. We had too few subjects to address the effect of HBeAg on serologic clearance of HBsAg. Among the recipients who did or did not have serologic clearance of HBsAg after BMT, there were no significant differences in terms of necroinflammatory and fibrosis scores or in hepatocyte staining of HBcAg and HBsAg. However, one shortcoming of the histologic studies was that biopsies were obtained before the start of famciclovir therapy-≥1-8 weeks before marrow infusion.
The use of BMT to treat chronic HBV infection is limited by the morbidity and mortality and the high expense associated with the procedure. Modification of this approach, such as infusions of anti-HBs-positive lymphocytes, might reduce the number of complications. Recently, adoptive transfer of immunity to HBsAg was shown to be induced through immunization of bone marrow donors or transplantation of peripheral blood lymphocytes [46, 47] . In the future, a better understanding of the underlying mechanism of adoptive immunity transfer with or without the use of nucleoside analogues might allow us to design better therapeutic strategies for chronic HBV patients (especially during the immune tolerant phase).
